Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Acute Traumatic Pain
NCT02866071Phase 3Active, not recruiting
- Start
- Oct 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in Acute traumatic pain. Primary endpoint: Reduction in Pain at 30 months. Started Oct 2017; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
Acute traumatic pain
Beyond the preview
Go deeper on NCT02866071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866071.